Chesapeake Asset Management LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 28.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,860 shares of the biopharmaceutical company’s stock after selling 4,000 shares during the quarter. Chesapeake Asset Management LLC’s holdings in Pfizer were worth $331,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of PFE. K.J. Harrison & Partners Inc raised its holdings in shares of Pfizer by 11.9% during the first quarter. K.J. Harrison & Partners Inc now owns 48,639 shares of the biopharmaceutical company’s stock worth $1,664,000 after purchasing an additional 5,159 shares during the period. Callahan Advisors LLC raised its holdings in shares of Pfizer by 1.9% during the first quarter. Callahan Advisors LLC now owns 279,334 shares of the biopharmaceutical company’s stock worth $9,556,000 after purchasing an additional 5,176 shares during the period. Beaumont Financial Partners LLC raised its holdings in shares of Pfizer by 17.1% during the first quarter. Beaumont Financial Partners LLC now owns 8,597 shares of the biopharmaceutical company’s stock worth $294,000 after purchasing an additional 1,254 shares during the period. Grandfield & Dodd LLC raised its holdings in shares of Pfizer by 0.3% during the first quarter. Grandfield & Dodd LLC now owns 83,230 shares of the biopharmaceutical company’s stock worth $2,847,000 after purchasing an additional 250 shares during the period. Finally, Usca Ria LLC raised its holdings in shares of Pfizer by 19.6% during the first quarter. Usca Ria LLC now owns 331,931 shares of the biopharmaceutical company’s stock worth $11,355,000 after purchasing an additional 54,492 shares during the period. 69.34% of the stock is currently owned by institutional investors.
In other news, EVP Frank A. Damelio sold 94,409 shares of the firm’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $3,209,906.00. Following the completion of the transaction, the executive vice president now owns 337,389 shares in the company, valued at approximately $11,471,226. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $35.65, for a total transaction of $262,027.50. Following the transaction, the executive vice president now owns 117,432 shares of the company’s stock, valued at approximately $4,186,450.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 366,557 shares of company stock worth $12,532,406. 0.06% of the stock is owned by corporate insiders.
Pfizer Inc. (PFE) traded up $0.06 during trading on Monday, reaching $35.49. 6,397,300 shares of the company’s stock traded hands, compared to its average volume of 20,093,064. The firm has a market cap of $211,545.50, a PE ratio of 14.20, a price-to-earnings-growth ratio of 2.51 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer Inc. has a 52-week low of $30.51 and a 52-week high of $36.78.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. Pfizer’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter last year, the company earned $0.61 EPS. equities research analysts anticipate that Pfizer Inc. will post 2.6 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.61%. Pfizer’s payout ratio is 79.01%.
A number of analysts recently weighed in on PFE shares. BMO Capital Markets raised shares of Pfizer from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $33.00 to $37.00 in a report on Wednesday, August 2nd. UBS AG reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Pfizer in a report on Monday, July 31st. ValuEngine raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, Morgan Stanley raised shares of Pfizer from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $35.00 to $39.00 in a report on Wednesday, September 20th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $38.66.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.